# Statin TReatment for COVID-19 to Optimise NeuroloGical recovERy

> **NCT04904536** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **The George Institute** · enrollment: 190 (actual)

## Conditions studied

- Neurocognitive Impairment, Mild

## Interventions

- **DRUG:** Atorvastatin
- **OTHER:** Standard Care

## Key facts

- **NCT ID:** NCT04904536
- **Lead sponsor:** The George Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-10
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-07-30
- **Target enrollment:** 190 (ACTUAL)
- **Last updated:** 2025-04-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04904536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04904536, "Statin TReatment for COVID-19 to Optimise NeuroloGical recovERy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04904536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*